Copyright Reports & Markets. All rights reserved.

Global Orally Administered Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Orally Administered Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Rotavirus Vaccine
    • 1.3.3 Cholera Vaccine
    • 1.3.4 Oral Polio Vaccine
    • 1.3.5 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Orally Administered Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Public
    • 1.4.3 Private
  • 1.5 Global Orally Administered Vaccine Market Size & Forecast
    • 1.5.1 Global Orally Administered Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Orally Administered Vaccine Sales Quantity (2021-2032)
    • 1.5.3 Global Orally Administered Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Merck
    • 2.1.1 Merck Details
    • 2.1.2 Merck Major Business
    • 2.1.3 Merck Orally Administered Vaccine Product and Services
    • 2.1.4 Merck Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Merck Recent Developments/Updates
  • 2.2 GSK
    • 2.2.1 GSK Details
    • 2.2.2 GSK Major Business
    • 2.2.3 GSK Orally Administered Vaccine Product and Services
    • 2.2.4 GSK Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 GSK Recent Developments/Updates
  • 2.3 Sanofi
    • 2.3.1 Sanofi Details
    • 2.3.2 Sanofi Major Business
    • 2.3.3 Sanofi Orally Administered Vaccine Product and Services
    • 2.3.4 Sanofi Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Sanofi Recent Developments/Updates
  • 2.4 Lanzhou Institute
    • 2.4.1 Lanzhou Institute Details
    • 2.4.2 Lanzhou Institute Major Business
    • 2.4.3 Lanzhou Institute Orally Administered Vaccine Product and Services
    • 2.4.4 Lanzhou Institute Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Lanzhou Institute Recent Developments/Updates
  • 2.5 Serum Institute
    • 2.5.1 Serum Institute Details
    • 2.5.2 Serum Institute Major Business
    • 2.5.3 Serum Institute Orally Administered Vaccine Product and Services
    • 2.5.4 Serum Institute Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Serum Institute Recent Developments/Updates
  • 2.6 Valneva
    • 2.6.1 Valneva Details
    • 2.6.2 Valneva Major Business
    • 2.6.3 Valneva Orally Administered Vaccine Product and Services
    • 2.6.4 Valneva Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Valneva Recent Developments/Updates
  • 2.7 Shanghai United Cell
    • 2.7.1 Shanghai United Cell Details
    • 2.7.2 Shanghai United Cell Major Business
    • 2.7.3 Shanghai United Cell Orally Administered Vaccine Product and Services
    • 2.7.4 Shanghai United Cell Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Shanghai United Cell Recent Developments/Updates
  • 2.8 Bibcol
    • 2.8.1 Bibcol Details
    • 2.8.2 Bibcol Major Business
    • 2.8.3 Bibcol Orally Administered Vaccine Product and Services
    • 2.8.4 Bibcol Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Bibcol Recent Developments/Updates
  • 2.9 PaxVax
    • 2.9.1 PaxVax Details
    • 2.9.2 PaxVax Major Business
    • 2.9.3 PaxVax Orally Administered Vaccine Product and Services
    • 2.9.4 PaxVax Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 PaxVax Recent Developments/Updates
  • 2.10 Vabiotech
    • 2.10.1 Vabiotech Details
    • 2.10.2 Vabiotech Major Business
    • 2.10.3 Vabiotech Orally Administered Vaccine Product and Services
    • 2.10.4 Vabiotech Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Vabiotech Recent Developments/Updates
  • 2.11 Tiantan Biological
    • 2.11.1 Tiantan Biological Details
    • 2.11.2 Tiantan Biological Major Business
    • 2.11.3 Tiantan Biological Orally Administered Vaccine Product and Services
    • 2.11.4 Tiantan Biological Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Tiantan Biological Recent Developments/Updates
  • 2.12 EuBiologics
    • 2.12.1 EuBiologics Details
    • 2.12.2 EuBiologics Major Business
    • 2.12.3 EuBiologics Orally Administered Vaccine Product and Services
    • 2.12.4 EuBiologics Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 EuBiologics Recent Developments/Updates
  • 2.13 Panacea Biotec Ltd
    • 2.13.1 Panacea Biotec Ltd Details
    • 2.13.2 Panacea Biotec Ltd Major Business
    • 2.13.3 Panacea Biotec Ltd Orally Administered Vaccine Product and Services
    • 2.13.4 Panacea Biotec Ltd Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Panacea Biotec Ltd Recent Developments/Updates
  • 2.14 Bio-Med
    • 2.14.1 Bio-Med Details
    • 2.14.2 Bio-Med Major Business
    • 2.14.3 Bio-Med Orally Administered Vaccine Product and Services
    • 2.14.4 Bio-Med Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Bio-Med Recent Developments/Updates
  • 2.15 Halfkin Bio-Pharmaceuticals
    • 2.15.1 Halfkin Bio-Pharmaceuticals Details
    • 2.15.2 Halfkin Bio-Pharmaceuticals Major Business
    • 2.15.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product and Services
    • 2.15.4 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Halfkin Bio-Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Orally Administered Vaccine by Manufacturer

  • 3.1 Global Orally Administered Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Orally Administered Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global Orally Administered Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Orally Administered Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Orally Administered Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Orally Administered Vaccine Manufacturer Market Share in 2025
  • 3.5 Orally Administered Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Orally Administered Vaccine Market: Region Footprint
    • 3.5.2 Orally Administered Vaccine Market: Company Product Type Footprint
    • 3.5.3 Orally Administered Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Orally Administered Vaccine Market Size by Region
    • 4.1.1 Global Orally Administered Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Orally Administered Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global Orally Administered Vaccine Average Price by Region (2021-2032)
  • 4.2 North America Orally Administered Vaccine Consumption Value (2021-2032)
  • 4.3 Europe Orally Administered Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Orally Administered Vaccine Consumption Value (2021-2032)
  • 4.5 South America Orally Administered Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Orally Administered Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Orally Administered Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global Orally Administered Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global Orally Administered Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Orally Administered Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global Orally Administered Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global Orally Administered Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Orally Administered Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America Orally Administered Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America Orally Administered Vaccine Market Size by Country
    • 7.3.1 North America Orally Administered Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Orally Administered Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Orally Administered Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe Orally Administered Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe Orally Administered Vaccine Market Size by Country
    • 8.3.1 Europe Orally Administered Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Orally Administered Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Orally Administered Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Orally Administered Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Orally Administered Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Orally Administered Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Orally Administered Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Orally Administered Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America Orally Administered Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America Orally Administered Vaccine Market Size by Country
    • 10.3.1 South America Orally Administered Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Orally Administered Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Orally Administered Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Orally Administered Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Orally Administered Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Orally Administered Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Orally Administered Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Orally Administered Vaccine Market Drivers
  • 12.2 Orally Administered Vaccine Market Restraints
  • 12.3 Orally Administered Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Orally Administered Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Orally Administered Vaccine
  • 13.3 Orally Administered Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Orally Administered Vaccine Typical Distributors
  • 14.3 Orally Administered Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Orally Administered Vaccine market size was valued at US$ 3059 million in 2025 and is forecast to a readjusted size of US$ 4442 million by 2032 with a CAGR of 5.5% during review period.
    Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
    The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
    This report is a detailed and comprehensive analysis for global Orally Administered Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Orally Administered Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Orally Administered Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Orally Administered Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Orally Administered Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Orally Administered Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Orally Administered Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol, PaxVax, Vabiotech, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Orally Administered Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Rotavirus Vaccine
    Cholera Vaccine
    Oral Polio Vaccine
    Other
    Market segment by Application
    Public
    Private
    Major players covered
    Merck
    GSK
    Sanofi
    Lanzhou Institute
    Serum Institute
    Valneva
    Shanghai United Cell
    Bibcol
    PaxVax
    Vabiotech
    Tiantan Biological
    EuBiologics
    Panacea Biotec Ltd
    Bio-Med
    Halfkin Bio-Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Orally Administered Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Orally Administered Vaccine, with price, sales quantity, revenue, and global market share of Orally Administered Vaccine from 2021 to 2026.
    Chapter 3, the Orally Administered Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Orally Administered Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Orally Administered Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Orally Administered Vaccine.
    Chapter 14 and 15, to describe Orally Administered Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now